Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV

Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Egyptian Patients With HCV

This prospective study was conducted at Ain Shams University Hospital, Internal Medicine, Hepatology and Gastroenterology Department, and Tropical Medicine Department.

To compare the efficacy of the combination of sofosbuvir and simeprevir for 12 weeks with the combination of sofosbuvir and ribavirin for 24 weeks in Egyptian patients with HCV-related Child A cirrhosis.

Inclusion Criteria:

• Patients with chronic HCV infection with a positive HCV RNA level by PCR.

Exclusion Criteria:

• Total bilirubin > 2 mg/dl.
• serum albumin < 2.8 g/dl.
• INR > 1.7.
• platelet count < 50000/mm3.
• serum creatinine > 2.5 mg/dl.
• patients presented by ascites or hepatic encephalopathy.
• patients with evidence of other causes of liver diseases, including hepatitis A, hepatitis B, autoimmune hepatitis, alcoholic liver disease, drug-induced hepatitis, haemochromatosis, Wilson disease or alpha-1 antitrypsin deficiency.
• patients with any advanced systemic disease.
• pregnancy or inability to use effective contraception in females.